| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| ENDP has a current Overall Rating of B (Positive). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Endo Pharmaceuticals Holdings Incorporation | 42 |
$65 |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Endo Pharmaceuticals Hlds | 8 |
$35 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ENDO PHARMACEUTICALS HOLDINGS INC (ENDP=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ENDO PHARMACEUTICALS HOLDINGS INC (ENDP=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for ENDP. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ENDO PHARMACEUT -- ENDP | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: BVF , ELN , ENDP , KG , MYL , WCRX -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ENDP: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
1.48% Nasdaq 
Research Reports
